Fac Rev. 2021 Apr 7;10:36. doi: 10.12703/r/10-36. eCollection 2021.
ABSTRACT
Radioactive iodine (RAI) 131I is a targeted therapy for patients with RAI-avid follicular cell-derived thyroid cancer. However, the responsiveness to 131I therapy varies among thyroid cancer patients mainly owing to differential RAI uptake and RAI radiosensitivity among patients' lesions. A personalized approach to maximize 131I therapeutic efficacy is proposed based on rec ent scientific advances and future opportunities.
PMID:33977289 | PMC:PMC8103907 | DOI:10.12703/r/10-36
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου
Σημείωση: Μόνο ένα μέλος αυτού του ιστολογίου μπορεί να αναρτήσει σχόλιο.